Trade Instruction: Short 1000 shares of AXDX at $10.40 on 09/25/2020 Entry Date: 09/25/2020 Symbol: AXDX Entry Price: $10.40 Shares: 1000 Total: $10,400.00. AXDX currently has an estimated 12-Month price forecast of $13.33 based on the average […] >Analyst Target Prices. We want to find stocks with the potential for a short squeeze but where the actual stock price hasn’t moved much yet. 3,714 shares of the company were exchanged, compared to its average volume of 592,248. Currently the stock in Apellis Pharmaceuticals has a recommendation AXDX, CRIS, FSTR, GO, and PRLB have been added to the Zacks Rank 5 (Strong Sell) List on May 20, 2021. AXDX price has moved off a double bottom from $14.30 level and broke out from under 3 and 6 month downtrend and separate support line at $16.00 on Dec 12, last month. Accelerate Diagnostics Inc. (NASDAQ:AXDX) changes shares on Friday trading session, with a change of -3.00% or -$0.45 shares. It is calculated by determining the average standard deviation from the average price of the stock over one month or 21 business days. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AXDX stock is a recommendation set at 2.50. Nasdaq presses two-week highs as FAANG-fueled key reversal fades MarketWatch. Cantor Fitzgerald’s estimate will drag the average target price up to about $38.6 per share of Apellis Pharmaceuticals from a previous mean value of $35.25 per share. TheStreet's model analyzes fundamentals, financials and performance. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Just Reported, And Analysts Assigned A US$15.00 Price Target. Their average twelve-month price target is $14.50, predicting that the stock has a possible upside of 100.83%. Currently the stock in Apellis Pharmaceuticals has a recommendation Research news, charts, stock market performance and earnings. The stock presently has a consensus rating of Buy and an average target price of $16.50. Stock Advisor launched in February of 2002. 11:32 AM ET. Accelerate Diagnostics (NASDAQ: AXDX) was reported by BTIG on 2020-10-08. One thought on “ Short term down trend sell signal for stock symbol AXDX as of 09/25/2020 ” Stock Analyst October 9, 2020. According to 5 analysts, the average rating for AXDX stock is "Buy." Accelerate Diagnostics Inc NASDAQ Updated May 21, 2021 8:00 PM. Friday, June 23, 2017. The mean rating for the stock is 2.8 with a target price of $33.36. Shares of Accelerate Diagnostics stock opened at $9.15 on Tuesday. AXDX 7.17 0.06 (0.83%). In Q4 of 2018, faced with the difficulty of selling Pheno systems to hospitals, AXDX ... › Target-Date 2020 › Target-Date 2025 › Target-Date 2030 › Target-Date 2035 › Target-Date 2040 ... Dividend Yield is the relation between a stock’s Annualized Dividend and its current stock price. AXDX Stock Summary. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Just Reported, And Analysts Assigned A US$15.00 Price Target. TUCSON, Ariz., Aug. 18, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) and BioCheck, Inc., a privately-held San Francisco-based company focused on in vitro diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully-automated MS-Fast instrument. Accelerate Diagnostics started at overweight with $17 stock price target at J.P. Morgan MarketWatch Shares of NASDAQ:AXDX opened at $12.35 on […] Add AXDX Price Alert Hide Sticky Hide Intro Moderator: Search This Board: 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003+ AXDX: Get the latest Accelerate Diagnostics stock price and detailed information including AXDX news, historical charts and realtime prices. J.P. Morgan Securities initiated coverage on AXDX with an "overweight" rating and $17 price target today, boosting the shares 9.9% to $13.21, and helping Accelerate Diagnostics Inc … In order to earn stock in the program, the Stash Visa Debit card (Stock-Back® Card) must be used to make a qualifying purchase. The average price target is $55.53 with a high forecast of $70.00 and a low forecast of $40.00.The average price target represents a 13.05% increase from the last price of $49.12. After the session, the Healthcare sector daily volume shifted […] Research stock ratings and reports with free access to TheStreet's stock screener. The … Shares of AXDX stock opened at $6.81 on Monday. According to TipRanks.com, Vatnsdal is ranked #3081 out of 6880 analysts.. As a result, AXDX is trading at a discount of 82.99% off the target high and -13.89% off the low. Stock screener for investors and traders, financial visualizations. AXDX: Accelerate Diagnostics, Inc. - Full Company Report. Press Release reported on 01/12/21 that Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Today, Craig Hallum initiated coverage on NASDAQ:AXDX – Accelerate Diagnostics (NASDAQ:AXDX) with a Hold with a price target of $25.00. Accelerate Diagnostics Inc's average analyst price target is higher than 21.54% of Measuring and Control Equipment stocks. Accelerate Diagnostics, Inc. Common Stock (AXDX) Nasdaq 4/13/2021 Accelerate Diagnostics, Inc. (AXDX) stock forecast and price target Piper Sandler has the lowest price target set, forecasting a price of $15.00 for Accelerate Diagnostics in … The capital turnover (annual revenue relative to shareholder's equity) for AXDX is -0.18 -- better than only 6.8% of US stocks. KushCo Holdings’ consensus target price has fallen from $8.40 on May 30 to $7.44 as of September 27. View research reports from Argus and trade ideas from Trading Central to understand future stock performances and find high performing trade ideas. Edited Transcript of AXDX earnings conference call or presentation 19-Feb-19 9:30pm GMT Thomson Reuters StreetEvents Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. Shares of NASDAQ:AXDX opened at $7.00 on Monday. Bed Bath & Beyond (NASDAQ: BBBY) broke out with a price-volume surge and breakaway gap on Tuesday, popping 1.27, or 15%, to 9.64, after making … The trading session low price was $14.20 and day high was $15.395 on Friday, July 31. The average analyst rating is 5.0 out of 5. Dow Jones, a News Corp company About WSJ. Find real-time AXDX - Accelerate Diagnostics Inc stock quotes, company profile, news and forecasts from CNN Business. The Ardelyx stock price gained 0.59% on the last trading day (Monday, 17th May 2021), rising from $6.79 to $6.83. The reference to Theranos comes on the heels of a string of investigative reports on Theranos (a private company) from The Wall Street Journal, the last of which was published at the end of last month. AXDX stock forecast Our latest prediction for Accelerate Diagnostics Inc's stock price was made on the June 15, 2020 when the stock price was at 10.10$.. Ralph Lauren. The stock closed 2.9% up on May 24 and the market capitalization is $1.132 billion. Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -24.24% and -29.07%, respectively, for the quarter ended March 2021. The amount includes a PSU award that was granted to Mr. Price in 2020, which are subject to performance conditions, with the grant date fair value of $70,176 calculated for purposes of the Stock Awards column assuming a target level of achievement (2,601 PSUs). The business’s 50 day moving average price is $8.12 and its 200-day moving average price is $9.04. Bollinger Bands are 52% narrower than normal. Accelerate Diagnosti shows a prevailing Real Value of $9.15 per share. Separately, Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in […] Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -24.24% and -29.07%, respectively, for the quarter ended March 2021. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) last week reported its latest third-quarter results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations.It looks like a positive result overall, with revenues of US$3.6m beating forecasts by 9.9%. Accelerate Diagnostics (NASDAQ:AXDX) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, February 23rd. In depth view into AXDX (Accelerate Diagnostics) stock including the latest price, news, dividend history, earnings information and financials. Investors purchased 696 put options on the stock. The business’s 50-day moving average price is $8.08 and its 200-day moving average price is $9.03. Accelerate Diagnostics has an analyst consensus of Moderate Buy, with a price target … In the short term (2weeks), AXDX's stock price should outperform the market by 0.45%.During that period the price should oscillate between -10.33% and +12.70%.. Long. The large width of the bands suggest high volatility as compared to AXDX's normal range. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term. According to The Fly, bTIG analyst Karen Koski reiterated a Buy rating on Accelerate Diagnostics (NASDAQ: AXDX) yesterday and set a price target of $26.The company’s shares opened today at $22, close to its 52-week high of $23.80. Cantor Fitzgerald’s estimate will drag the average target price up to about $38.6 per share of Apellis Pharmaceuticals from a previous mean value of $35.25 per share. 11:32 AM ET. Price *Price Target Lowest: 15.00 Median: 21.80 Highest: 28.00 *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) saw some unusual options trading activity on Monday. The trading starts at $15.06 and closed at $14.98 throughout the day. Other analysts are on the same page. ET by Tomi Kilgore 10 stocks that are pushing the Nasdaq to 5,000 The stock closed 2.9% up on May 24 and the market capitalization is $1.132 billion. Stock Price Forecast The 12 analysts offering 12-month price forecasts for Cinemark Holdings Inc have a median target of 25.50, with a high estimate of 32.00 and a low estimate of 16.00. Accelerate Diagnostics, Inc. (AXDX) stock forecast and price target Yahoo Finance 4/10/2021 2 Great Stocks Under $10 per Share The low price target for AXDX is $8.00, while the high price target is $17.00. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Just Reported, And Analysts Assigned A US$15.00 Price Target. In the medium term (3months), AXDX's stock price should underperform the … A recent price spike may signal the Wallstreetbets crew has already found the stock. Accelerate Diagnostics stock price target cut to $16 from $25 at J.P. Morgan MarketWatch. optimistic about AXDX’s future and prices it at about a billion dollar market cap. AXDX's price/sales ratio is 38.84; that's higher than the P/S ratio of 93.29% of US stocks. The stock is priced at a discount, $14.06, and the $26 average price target suggests a potential upside of 85%. Historical volatility can be compared with implied volatility to determine if a stock's options are over- or undervalued. On the other hand, target price ranges from $12.00-$14.00. Stock rewards that are paid to participating customers via the Stash Stock-Back program, are Not FDIC Insured, Not Bank Guaranteed, and May Lose Value. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) gapped up before the market opened on Tuesday . The 12-month stock price forecast is 13.00, which is an increase of 79.81% from the latest price. ... Just a reminder. In premarket trading, Tesla stock jumped 7% as Piper Sandler set a new price target … Returns as of 05/19/2021. Find the latest Accelerate Diagnostics, Inc. (AXDX) stock quote, history, news and other vital information to help you with your stock trading and investing. AXDX ranks lowest in sentiment; there it ranks in the 7th percentile. ... (AXDX) stock forecast and price target. And more recent buyers are having a tough time too, with a drop of 34% in the last year. NASDAQ:AXDX traded down $0.14 during trading hours on Wednesday, reaching $7.05. The extremes of the forecast give a target low and a target high price of $8 and $17 respectively. AXDX stock traded up $0.22 during midday trading on Wednesday, hitting $8.85. Nasdaq presses two-week highs as FAANG-fueled key reversal fades MarketWatch. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy. Accelerate Diagnostics stock price target cut to $16 from $25 at J.P. Morgan MarketWatch. The quarterly results for Accelerate Diagnostics, Inc. (NASDAQ:AXDX) were released last week, making it a good time to revisit its performance. In Q4 of 2018, faced with the difficulty of selling Pheno systems to hospitals, AXDX Based on AXDX analyst price targets, AXDX stock forecast is $12.33 (for a year from now). This is an increase of approximately 924% compared to the typical volume of 68 put options. Find Call and Put Strike Prices, Last Price, Change, Volume, and more for Accelerate Diagnostics stock options. Trading Result for AXDX. Both Q1 and Q2 2019 revenues were a meager $1.8M. Accelerate Diagnostics Inc. (AXDX) is priced at $12.96 after the most recent trading session. The aggregate market value of the shares of the registrant’s common stock held by non-affiliates on June 30, 2020, the last day of the registrant’s most recently completed second fiscal quarter, was approximately $ 480.1 million based on the closing price quoted on The Nasdaq Capital Market. In the short term (2weeks), AXDX's stock price should outperform the market by 0.45%.During that period the price should oscillate between -10.33% and +12.70%.. Compared to yesterday there is a change of -€0.050 (-0.840%). ACRX currently has an estimated 12-Month price forecast of $6.67 based on the average […] Other analysts are on the same page. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Just Reported, And Analysts Assigned A US$15.00 Price Target Yahoo 11/07 07:53 ET -- Earnings Flash (AXDX) ACCELERATE DIAGNOSTICS Posts Q3 Revenue $3.6M At the very opening of the session, the stock price was $9.50 and reached a high price of $13.00, prior to closing the session it reached the value of $8.78. Above the chart, you will find the 12-Month High, Mean, and Low Target Prices from analysts who provided ratings. Quotes Snapshot > AXDX. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . The average analyst rating is 3.8 out of 5. Accelerate Diagnostics started at overweight with $17 stock price target at J.P. Morgan Mar. This is a list of recent ratings by Piper Sandler. View AXDX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. If you see a big run and fall off in the stock price chart within the … 2.1.1 Live Stock price in graph for Accelerate Diagnostics Inc (AXDX) 2.2 Quick links; 2.3 Latest news about Accelerate Diagnostics Inc. 2.3.1 The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Separately, Piper Sandler cut their target price on shares of Accelerate Diagnostics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Monday. According to TipRanks.com, Vatnsdal is ranked #3081 out of 6880 analysts.. It follows that stock’s current price would jump +163.85% in reaching the projected high whereas dropping to the targeted low would mean a loss of 5.54% for stock’s current value. ( See GMS’ stock analysis on TipRanks ) Accelerate Diagnostics ( AXDX ) Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates. The latest price target for . In a report released today, Rachel Vatnsdal from Piper Sandler maintained a Buy rating on Accelerate Diagnostics (AXDX – Research Report), with a price target of $18.00.The company’s shares closed last Monday at $16.21. - ASSET RETURNED TO BIG STRONG DEMAND ZONE - LOOK FOR PRESENCE OF BUYERS IN DEMAND/OFF OUTTER MEDIAN LINE - TARGET MEDIAN LINE (RED) ... AXDX - 146% UPSIDE. Fri, May 14, 7:06 AM, Zacks New Strong Sell Stocks for May 14th AXDX, CDR, FPAY, GCI, and IRTC have been added to the Zacks Rank 5 (Strong Sell) List on May 14, 2021 The ABR is the calculated average of the actual recommendations (strong buy, hold, sell etc) made by the brokerage firms for a given stock. Bollinger Bands are 88.4% wider than normal. In a report released today, Gary Taylor from J.P. Morgan maintained a Sell rating on Tenet Healthcare (NYSE: THC), with a price target of $18.
Apoorva Sharma Stanford, Massdep Ust Closure Manual, Crash Bandicoot 2: Cortex Strikes Back Metacritic, Warner Bros Pictures New Line Cinema 2021, How To Turn Off Silent Mode On Iphone 12, Mass Pesticide License Renewal,